We are reviewing individual medicines or smaller groups of medicines, within areas where we judge there to be greatest reason to question whether the medicine provides cost-effective utility. The balance between medicines cost effective utility changes though over time when for example new medicines are included in the high-cost threshold or when we accept new pricing for a medicine.
Prior to commencing a new review we make detailed prioritization analyses where we, in part, look at sales volumes, reimbursement costs, cost per DDD, expanded indications and expired patents. We also hold a dialogue with the county councils and provide them with an opportunity to submit suggestions on which products we should review.
We may also start a review in connection with evaluating an application for a new medicine to be part of the reimbursement system. We start a review like this if there are deficiencies in the area when it comes to usage or cost-effectiveness.